What is Virscio?
Virscio is a dedicated team of scientists and innovators focused on tackling critical human health challenges through advanced biomedical research. The company provides a comprehensive suite of services, including contract research, preclinical services, and collaborative research initiatives. By leveraging human-relevant test systems, Virscio aims to deliver actionable data, thereby reducing the time, cost, and inherent risks associated with translating scientific concepts into successful clinical outcomes. Their commitment to continuous innovation supports therapeutic advancements, further bolstered by their new pathology and Tissue Pharmacodynamics Services Division, which expands their research capabilities.
How much funding has Virscio raised?
Virscio has raised a total of $150K across 1 funding round:
Debt
$150K
Debt (2020): $150K with participation from PPP
Key Investors in Virscio
PPP
Public-Private Partnership
What's next for Virscio?
The substantial capital infusion, particularly the recent strategic investment, suggests Virscio is poised for significant expansion and further innovation in its service offerings. This late-stage funding will likely be allocated towards scaling operations, enhancing research infrastructure, and potentially broadening its market reach. The company's focus on reducing development risks and accelerating therapeutic progress indicates a strategic direction aimed at solidifying its position as a key partner in the biomedical research ecosystem. Future developments may include strategic partnerships or acquisitions to further enhance its capabilities and impact on human health.
See full Virscio company page
